Veracyte, Inc.

As we near the end of October and Breast Cancer Awareness Month, watch this video with insights from a conversation Sam Jole, Associate Director of Medical Affairs, was honored to have with Joyce, a resilient breast cancer survivor diagnosed at age 72. Joyce, alongside her daughter Lisa, courageously sought alternatives to chemotherapy, hoping for a treatment plan tailored to her specific therapy needs. Together, they explored options to determine whether chemotherapy was necessary or if a different approach would be more beneficial. With the help of Veracyte’s #Prosigna test, they gained the knowledge needed to decide that an endocrine-targeted treatment was the right path forward for Joyce. 💗 A special thank you to Joyce and Lisa for telling us their deeply personal cancer journey. Their bravery inspires us all and strengthens our fight against cancer. 💗 Read article to learn more about Prosigna test’s impact on breast cancer worldwide: https://lnkd.in/enbspQ4k #oncology #breasthealth #breastcancerawareness #breastcancerresearch #breastcancersupport #breastcancertreatment #BCSM #fightbreastcancer #PinkOctober #pinktober #thinkpink #oncology #womenshealth #Prosigna #Prosignatest

Genomic testing represents an exciting breakthrough in #breastcancer treatment, offering a path to more effective care. As we honor #BreastCancerAwarenessMonth, we invite you hear from #Prosigna's Senior Marketing Manager, Laure Gaboriaud, as she shares how Veracyte’s #ProsignaBreastCancerAssay is becoming increasingly available to women around the world. Read article to learn more: https://lnkd.in/enbspQ4k #oncology #breasthealth #breastcancerawareness #breastcancerresearch #breastcancersupport #breastcancertreatment #BCSM #fightbreastcancer #PinkOctober #pinktober #thinkpink #oncology #womenshealth #Prosigna #Prosignatest

We invite you to hear from Veracyte’s Executive Director, Breast Cancer Assay Marketing, Jenna Lefkowits, who, in honor of #BreastCancerAwarenessMonth, reaffirms our company’s commitment to empower physicians and patients with evidence-based tools and resources that support more confident, personalized #breastcancer treatment decisions. Learn more about our #Prosigna Test's Impact on Breast Cancer Worldwide: https://lnkd.in/enbspQ4k #oncology #breasthealth #breastcancerawareness #breastcancerresearch #breastcancersupport #breastcancertreatment #BCSM #fightbreastcancer #PinkOctober #pinktober #thinkpink #oncology #womenshealth #Prosignatest

This week, our CEO, Marc Stapley, shares insights on how Veracyte is helping to address equity gaps in healthcare and what sets our company apart. Additionally, two new studies suggest that #Decipher Prostate may help clinicians more accurately assess risk for prostate cancer patients eligible for active surveillance. Thank you for following our news: 1️⃣ Veracyte’s RNA Genetic Test Predicts Aggressive Prostate Cancer in Black Men – Jonathan D. Grinstein, PhD, Inside Precision Medicine 2️⃣ The Care Continuum: Veracyte’s CEO on its Diagnostic Strategy – Haydn Brain, OPTO 3️⃣ The Future is Bright for Veracyte and Molecular Diagnostics – OPTO 4️⃣ Genomic Testing Helps Personalize Care for Prostate Cancer Patients – Mark L. Fuerst, Oncology Times 🔗 Read the full articles and more on Veracyte in the news: https://lnkd.in/ga-zvGrd #prostatecancer #biotechindustry #biotechnology #biotech #MRDtechnology #genomictesting #cancertests #decipherprostatetest #moleculardiagnostics #VCYT

📣 New Research Insights: In this study, the analysis of discordant data further underscores findings that the 21-Gene Assay(OncotypeDX Breast Recurrence Score® test) has weak or no association with the prediction of #breastcancer recurrence in diverse populations and the 21-Gene score underestimates the true risk for recurrence, which can potentially result in undertreatment. This important comparison study concluded that #Prosigna’s ROR-P score, which includes molecular subtypes and a proliferation score, provides a more accurate prediction of recurrence risk, enabling healthcare providers to make better-informed treatment decisions, especially for underrepresented populations such as Black and younger women. Prosigna offers: 🧬 More accurate prognosis for diverse patients. 📊 Enhanced prediction of recurrence risk. 🎯 Better treatment guidance to reduce the risk of distant recurrence. Read the full study in JCO Precision Oncology: https://lnkd.in/gdRzVDu9 #oncology #Prosigna #breastcancerspecialists #precisionmedicine #breasthealth #breastcancerawareness #medicaloncologist #surgicaloncologist #breastcancerspecialist #oncologyassociations #breastcancerpatientadvocacygroups

We are pleased to announce new findings from the multicenter, prospective VANDAAM trial that show the #Decipher Prostate Genomic Classifier accurately predicts biochemical recurrence among African American men with early-stage prostate cancer. As a population that is disproportionately impacted by the disease, this offers clinicians an improvement over clinical factors alone in guiding #prostatecancer treatment decisions. The new data was shared today at the American Society for Radiation Oncology (ASTRO)’s annual meeting, #ASTRO24, in Washington, D.C. Read press release: https://lnkd.in/gzkbCAAi #prostatehealth #menshealth #earlydetectionsaveslives #urology #oncology #radiationoncology #oncologyresearch #genomictesting #DecipherProstate

One of the most exciting breakthroughs in #breastcancertreatment has been the use of genomic testing to enable more personalized and effective care. As we honor #BreastCancerAwarenessMonth and the women and their families around the world who are bravely battling this disease, we want to share some encouraging and hopeful progress being made to combat breast cancer. We invite you to explore this article with research and resources, offering further insights into the important impact of #genomictesting for breast cancer, particularly for diverse populations. It is our unwavering commitment to continue to expand access to Veracyte's #Prosigna Breast Cancer Assay to more women and their physicians around the world. #breastcancer #breasthealth #breastcancerawareness #breastcancerresearch #breastcancercommunity #breastcancersupport #breastcancertreatment #BCSM #fightbreastcancer #PinkOctober #pinktober #thinkpink #oncology #womenshealth #Prosignatest

As we continue to observe #ThyroidCancerAwarenessMonth, we invite you to visit The Social Butterfly, Afirma's blog dedicated to empowering patients, caregivers, and healthcare providers with the latest news, cutting-edge research, and expert education on thyroid cancer. Featuring insights from Joshua Klopper, MD, our medical director for Endocrinology at Veracyte, you’ll find discussions on topics that truly matter, including: • What is a Transcriptome?  • Recent Study Shows That, Yes, We Can Leave More Thyroids Intact • How TERT and Veracyte’s Afirma GSC Can Help Personalize Treatment Decisions in Thyroid Cancer  • New Research Presented at ENDO 2024 We hope you visit today and let us know in the form if there is anything we can do to help. https://lnkd.in/efbDKdAZ #thyroidhealth #thyroidawareness #thyroid #Veracyte 

New data highlight the weaknesses of the 21-Gene Assay (Oncotype DX Breast Recurrence Score® test) for predicting the breast cancer prognosis recurrence risk for diverse populations. A new study in JCO Precision Oncology shows researchers have identified significant gaps in industry-standard tests when it comes to predicting breast cancer recurrence risk across diverse populations, while highlighting #Prosigna’s ROR-P’s exceptional prognostic accuracy. Recognizing that every patient is unique, our test is designed to account for individual biological differences, ensuring the most precise prognosis regardless of ethnicity. If you would like to learn more, read the study in JCO Precision Oncology: https://bit.ly/47A63Tm #breastcancer #breasthealth #breastcancerawareness #medicaloncologist #surgicaloncologist #breastcancerspecialist #oncology #oncologyassociations #breastcancerpatientadvocacygroups

📢 This morning at #ESMO24, our CEO, Marc Stapley, spoke with BiotechTV to discuss groundbreaking new data supporting our plan to expand the use of the #DecipherProstate test to metastatic prostate cancer patients. This test, already guiding care for localized prostate cancer, now shows potential in predicting which patients could benefit from adding chemotherapy to androgen deprivation therapy, thanks to insights from an analysis of Decipher Prostate in a phase 3 trial of the multi-center, randomized STAMPEDE clinical trial. These findings are a significant step forward in precision medicine, enabling urologists and oncologists to tailor treatment more effectively with the potential to improve patient outcomes. Learn more about how we're transforming prostate cancer care with our innovative diagnostics. 👉 Watch the full interview with Marc Stapley on BioTech TV: https://lnkd.in/gNAeST4V #ProstateCancer #STAMPEDEStudy #PrecisionMedicine #Oncology #Urology #ProstateHealth #Veracyte #BioTechTV #CancerDiagnostics